



KemPharm to Participate in BIO Partnering @ JPM During “J.P. Morgan Week 2022”

January 6, 2022

CELEBRATION, Fla., Jan. 06, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today the company is participating in BIO Partnering @ JPM, which is being held virtually alongside the J.P. Morgan 40th Annual Healthcare Conference 2022.

Details of the events are as follows:

Event: BIO Partnering @ JPM
Date: January 10-14, 2022
Registration: <https://www.bio.org/events/bio-partnering-jpm/registration>

During BIO Partnering @ JPM, members of the KemPharm management team will participate in virtual one-on-one meetings with registered investors and pharmaceutical companies to discuss KemPharm's recent corporate achievements and anticipated milestones, its serdexmethylphenidate development pipeline, and commercial products, including AZSTARYS[®].

About AZSTARYS[®]:

AZSTARYS is an FDA-approved, once-daily product for the treatment of attention deficit hyperactivity disorder (ADHD) in patients age six years or older. AZSTARYS consists of SDX, KemPharm's prodrug of d-methylphenidate (d-MPH), co-formulated with immediate release d-MPH. Corium, Inc., a portfolio company of Gurnet Point Capital, is leading all commercialization efforts for AZSTARYS in the U.S.

The complete approved prescribing information for AZSTARYS may be downloaded in PDF format here: https://kempharm.com/wp-content/uploads/2021/03/AZSTARYS-Master-Label-Final_20210302.pdf

About KemPharm:

KemPharm is a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its proprietary LAT[®] (Ligand Activated Therapy) technology. KemPharm utilizes its proprietary LAT[®] technology to generate improved prodrug versions of FDA-approved drugs as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. KemPharm's prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, or ADHD, stimulant use disorder (SUD) and CNS rare diseases, including idiopathic hypersomnia (IH). In addition, the U.S. Food and Drug Administration (FDA) has approved AZSTARYS[®], a new once-daily treatment for ADHD in patients age six years and older containing KemPharm's prodrug, serdexmethylphenidate (SDX), and APADAZ[®], an immediate-release combination product containing benzhydrocodone, KemPharm's prodrug of hydrocodone, and acetaminophen. For more information on KemPharm and its pipeline of prodrug product candidates visit www.kempharm.com or connect with us on [Twitter](#), [LinkedIn](#), [Facebook](#) and [YouTube](#).

KemPharm Contacts:

[Tiberend Strategic Advisors, Inc.](#)

Jason Rando/Maureen McEnroe, CFA

(212) 375-2665 / 2664

jrando@tiberend.com

mmcenroe@tiberend.com



Source: KemPharm